Dysregulation of trauma regulation pathway treatment and monitoring techniques
The subject matter of the present disclosure generally relates to techniques for addressing or correcting dysregulation of the trauma regulation pathway. The dysregulation may be associated with a physiological condition, such as a SARS-CoV-2 viral infection. In an embodiment, the techniques include treating dysregulation based on a renin-angiotensin pathway molecule or cell and/or a splenic pathway molecule or cell using targeted neuromodulation. In an embodiment, neuromodulation is used to regulate the immune system, e.g., as an energy-based adjuvant for a vaccine.
1. A method for modulating an immune response in a subject, comprising:
applying ultrasound energy to an internal tissue of the subject, wherein the internal tissue is a gastrointestinal tissue;
measuring a change in concentration of circulating CCK in the subject after applying the ultrasound energy; and
determining, based on the change, that the applied ultrasound energy caused the change in concentration to the circulating CCK.
2. The method of claim 1 , wherein the internal tissue further comprises a liver tissue.
3. The method of claim 1 , wherein the applied ultrasound energy is focused or concentrated within a volume of less than about 25 mm 3 of the internal tissue.
4. The method of claim 1 , wherein applying the ultrasound energy causes a decrease in a concentration of circulating IL-6 relative to a baseline concentration before the energy is applied.
5. The method of claim 1 , wherein cleavage of the c-terminal dipeptide of CCK by angiotensin-converting enzyme (ACE) is associated with class switching of antibodies.